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Abstract  
Background 
Freely available and easily accessible (e.g. via the internet) written consumer 
health information (CHI) plays an increasingly important role in the treat-
ment decision process between patients and their health-care professionals. 
Criteria describing the quality of CHI have already been defined. However, 
there is criticism that they are not yet comprehensively addressed within ex-
isting CHI. This study aims at assessing the quality of written CHI about 
treatment options for chronic myeloid leukaemia (CML). 
Methods 
Written CHI materials were identified by an internet search in 3 search en-
gines and organisations (n=118) potentially offering written CHI on CML 
were directly contacted and asked to provide their patient information mate-
rials. Additionally, their websites were screened for relevant materials. The 
structural quality of the included materials was assessed with the standard-
ised quality appraisal instrument DISCERN by two independent raters. 
Results 
33 patient information materials about CML and its treatment options were 
included. The overall mean DISCERN rating (absolute rating based on 
questions 1-15: min 15 to max 75) was 44.12 (range 24 to 65, SD 11.49) and 
the overall mean DISCERN score (mean rating based on questions 1-15: min 
1 to max 5) was 2.94 (SD 0.766). Mean DISCERN scores show a statistically 
significant discrepancy in quality of the materials between the different 
types of information providers (p=0.012) but not between providers present-
ing a quality certification on their website and those without a quality label 
(p=0.385). 
Conclusion 
These results confirm that available CHI does not sufficiently meet existing 
quality criteria for patient information. Especially materials offered by 
commercial organisations have significantly lower DISCERN ratings than 
those offered by non-profit organisations. Astonishingly, materials of pro-
viders approved by quality labels such as Health-on-the-Net (HON), which 
claim to set apart trustworthy from non-trustworthy websites (e.g. potential 
for commercial influence), do not demonstrate higher quality than materials 
by providers without any quality labels. 
Keywords 
written patient information, consumer health information, CHI, chronic 
myeloid leukaemia, CML, shared decision making, SDM, DISCERN, qual-
ity appraisal 
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Zusammenfassung 
Hintergrund 
Neben dem Arzt-Patienten-Gespräch spielen frei verfügbare schriftliche Pa-
tienteninformationen für eine partizipative Entscheidungsfindung bei Be-
handlungsentscheidungen eine immer größere Rolle. Obwohl Kriterien für 
evidenzbasierte Patienteninformation verfügbar sind, werden diese bislang 
nur unzureichend berücksichtigt. Ziel der vorliegenden Studie ist es, die 
Qualität schriftlicher Patienteninformation zu evaluieren und Ansatzpunkte 
für die Qualitätsverbesserung zu finden. 
Methoden 
Zur Identifizierung von gebräuchlichen Patienteninformationen wurde eine 
Internetsuche in 3 Suchmaschinen durchgeführt. Zusätzlich wurden rele-
vante Organisationen und Institutionen (n=118) sowohl direkt angeschrie-
ben als auch deren Websites durchsucht. Die Bewertung der strukturellen 
Qualität der eingeschlossenen Patienteninformationen wurde von zwei un-
abhängigen Ratern anhand des standardisierten Qualitätsbewertungsin-
struments DISCERN durchgeführt. 
Resultate 
33 Informationsmaterialen zu CML und deren Behandlungsoptionen wur-
den eingeschlossen. Das mittlere DISCERN-Rating war (absolutes Rating 
der Fragen 1-15: Minimum 15 bis Maximum 75) 44,12 (Spannweite 24-65, 
SD 11,49) und der mittlere DISCERN-Score (mittleres Rating der Fragen 1-
15: Minimum 1 bis Maximum 5) war 2,94 (SD 0,766) für alle 33 eingeschlos-
senen Informationsmaterialien. Der mittlere DISCERN-Score variiert sta-
tistisch signifikant zwischen der Art der Informationsersteller (p=0,012) 
aber nicht zwischen Organisationen, die ein Qualitätszertifikat auf ihrer 
Homepage anzeigen, im Vergleich zu denen, die kein Qualitätslabel haben 
(p=0,385). 
Fazit 
Diese Ergebnisse bestätigen, dass derzeit verfügbare Gesundheitsinformati-
onen nur unzureichend bestehenden Qualitätskriterien entsprechen. Vor al-
lem Informationsmaterialien von auf Gewinn ausgerichteten Organisationen 
haben statistisch signifikant niedrigere DISCERN-Ratings als jene von 
Non-Profit-Organisationen. Erstaunlicherweise konnte kein Qualitätsunter-
schied zwischen Materialien von Organisationen mit einem Qualitätslabel, 
wie zum Beispiel Health on the Net (HON), auf deren Homepage im Ver-
gleich zu Organisationen ohne einem derartigen Qualitätszertifikat festge-
stellt werden.  
Schlüsselwörter 
Schriftliche Patienteninformation, Gesundheitsinformation, chronisch mye-
loische Leukämie, CML, Shared Decision Making, SDM, DISCERN, Quali-
tätsbewertung 
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1 Background 
1.1 The Role of Written Patient Information 
in the Field of Shared Decision Making 
Written patient information is regarded as an essential component of shared 
decision making (SDM) on diagnostic and therapeutic options. Studies show 
that within the last 10 years, the information behaviour of patients (and 
their relatives) regarding health issues has changed substantially. 80-90% of 
patients search by themselves in traditional media, the internet, via patient 
organisations or health insurers for specific or general health information 
[1]. Especially patients suffering from chronic disease and their relatives 
search proactively for health information additional to the information pro-
vided to them by health care professionals in order to obtain more certainty 
about their condition and the decision(s) related to their health problem [2, 
3]. One important prerequisite for informed SDM is the availability of evi-
dence-based information, which has been written for patients and lay audi-
ence [4]. Despite the definition of evidence-based patient information 
(EBPI) [5, 6], it is criticized that the components of EBPI (e.g.: natural 
course of the disease, available treatment options including their benefits 
and risks and also including the option of doing nothing, etc.) are not yet 
comprehensively addressed within existing patient information materials 
[4]. 
Patient information is not solely intended to be a service for patients or to 
support SDM. The Pharmaceutical Forum, an initiative of the European 
Commission, describes the value of accessible high-quality patient informa-
tion within various aspects of the health care setting and lists the following 
reasons on the importance of consumer health information for patients [7]:  
- “Enhance their ability to make informed decisions about optimal 
disease management and prevention in full partnership with health 
care professionals; 
- Optimise health outcomes through improved treatment concor-
dance based on the belief that the more patients are informed, the 
better they understand their treatment and in particular how medi-
cines must be taken; 
- Make more effective and rationale use of the therapies that are 
available; 
- Increase their awareness of benefits and risks of medicines and the 
importance of reporting and managing possible side effects and ad-
verse reactions; 
- Improve patients’ quality of life by adopting preventive measures, 
seeking earlier diagnosis, recovering faster from illness, avoiding 
hospitalisation and invasive surgery where possible, and enabling 
patients to continue their normal daily routines.” [7] 
 
written patient 
information is an 
essential component of 
SDM 
patient information is 
more than a service; it 
enhances informed 
decisions and aims to 
improve health overall 
Quality Appraisal of Written Consumer Health Information  
for Patients with Chronic Myeloid Leukaemia (CML) 
10 LBI-HTA | 2012 
These recommendations point out that the mere availability of patient in-
formation is not enough to ensure informed SDM and educated patients. 
Considering the known barriers for patients to access high-quality patient 
information (e.g. health literacy, time available, state of mind, confidential-
ity and lack of information / too much information), the Pharmaceutical Fo-
rum encourages EU member states to develop strategies to overcome these 
barriers in order to improve health outcomes [7]. Within this context, access 
to high-quality patient information has to be seen as one part of a process to 
improve health care overall and to strengthen health literacy. The World 
Health Organisation defines health literacy as the “achievement of a level of 
knowledge, personal skills and confidence to take action to improve personal 
and community health by changing personal lifestyles and living condi-
tions” [8]. This also includes strategies to facilitate access to high-quality 
and validated information, to raise awareness of what patients can and 
should expect from their health care professionals and to promote the in-
formation and communication process between both, the different health 
settings and the human contact between patients and their health profes-
sionals [7]. At this point it has to be noted that written patient information 
does not only play an important role in SDM, but is also very important in 
the context of health literacy in order to empower patients to make appro-
priate health decisions based on written or oral health care information. The 
concept of health literacy also encompasses the ability of people to access 
health information and their capacity to use the obtained information effec-
tively [9, 10].  
1.2 The Role of Written Patient Information 
in Hemato-Oncology 
Particularly in fields where multiple diagnostic and therapeutic options are 
available, reliable information for the patients to support the discussion 
with the physician about the most appropriate treatment choice is necessary. 
For instance, in oncology, stratified medicine has become more and more 
important over the last 20 years. For decades, intravenously administered 
cytotoxic chemotherapy was the standard of care for various cancer entities 
[11]. With the increased understanding of the mechanisms underlying a dis-
ease, drugs that specifically target the molecules involved in the growth of 
e.g. cancer cells, were developed to bind to these molecules and stop further 
growth or even lead to apoptosis [12]. Targeted therapies are often less toxic 
than traditional chemotherapy, as they interfere with specific molecules and 
not primarily through inhibition of cell division, which also affects healthy 
cells (e.g. hair, gastrointestinal epithelium, bone marrow) [11].  
The development and approval of targeted therapies has substantially 
changed the treatment management for some diseases. Further, the mode of 
application of the therapy is relevant for patients with respect to the extent 
to which therapy influences their daily life not only in terms of effectiveness 
and safety, but also whether they can take their medication by themselves at 
home or if they have to see a physician regularly or even stay in hospital dur-
ing treatment. Two of the main types of targeted agents are small molecule 
inhibitors and monoclonal antibodies [11, 12]. Small molecule inhibitors 
such as imatinib or erlotinib are administered orally and can thus be given 
in an outpatient setting, whereas monoclonal antibodies like rituximab and 
barriers to access high-
quality patient 
information … 
… e.g. health literacy 
 
 
WHO definition of 
health literacy 
patient information to 
support empowerment 
of patients 
reliable information is 
particularly important in 
fields with multiple 
diagnostic and / or 
therapeutic options 
e.g. in stratified 
medicine 
development of new 
drugs has changed 
treatment management 
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bevacizumab are administered intravenously in the hospital. Although the 
majority of cancer patients (>80%) prefer oral therapy over intravenous 
therapy due to the convenience of receiving treatment at home, avoidance of 
venepunctures, a greater sense of “control” over their treatment and better 
quality of life, there are concerns regarding the administration of therapy in 
this form. Specifically, oral administration of these medications is often as-
sociated with reduced effectiveness of treatment due to poor adherence, in-
adequate monitoring of adverse events and limited support of the patients 
by their oncology care team due to reduced contact [13]. In order to manage 
these challenges, education of both the patient and the oncology care team is 
essential [13, 14]. With the implementation of the new “innovative” drugs 
and the traditional therapy options still available, the question arises which 
of the treatment possibilities to choose for which patient and based on what 
kind of information patients have to decide together with their physicians 
on a specific treatment option. Without access to good-quality information 
about the therapy options and their benefits and harms, the advantages and 
disadvantages, patients will not be able to make informed choices regarding 
the therapy [15, 16].  
Nowadays, since SDM is an essential component in the treatment manage-
ment of patients, especially in chronically ill patients, it should be safe to as-
sume that information about these advances in medical research and treat-
ment is also provided to patients by reliable high-quality information to 
support decision making with their health professional. One example for the 
importance of SDM is chronic myeloid leukaemia (CML), a non-curable, 
complex and chronic disease with a variety of treatment options available. 
For a long time, chemotherapy and hematopoietic stem cell transplantation 
(HSCT) have been the standard of care in CML treatment showing, how-
ever, limited effectiveness [17]. In 2001, CML therapy was revolutionised 
with the approval of imatinib mesylate, a tyrosine kinase inhibitor (TKI), 
which improved the 5-year overall survival rates from 53% to 89% [18]. 
Within the last five years, two further TKIs for the treatment of CML have 
been approved. With the approval of these three small molecule inhibitors 
(imatinib mesylate, dasatinib and nilotinib) and the former treatment op-
tions (e.g. HSCT, therapy with interferon-alpha (IFN-α) or hydroxyuera 
[19]), there is now a range of treatment options available, each accompanied 
by a variety of advantages and disadvantages [20-23]. Adequate information 
materials on these treatment options would enable patients suffering from 
CML to be well-informed and therefore participate actively in their treat-
ment management process. Information may foster the awareness regarding 
the challenges of living with CML and the advantages, as well as the disad-
vantages of the therapy. This is why written patient information materials 
may be useful to support SDM between the oncology care team and the pa-
tient. Research in the field of high-quality patient information claims that 
quality criteria already defined are not yet comprehensively addressed 
within existing patient information materials. Therefore, this study aims to 
assess the structural quality of written patient information about CML and 
its treatment options. 
In the following paragraphs, a brief overview of the disease CML itself and 
the advantages and disadvantages of the available treatment options will be 
given. Further, it will be pointed out which parameters determine “quality” 
of written consumer information and how said quality can be assessed. 
SDM is an essential 
component in the 
treatment management 
of patients with chronic 
disease 
 
e.g. with CML 
 
development of new 
drugs (imatinib, 
dasatinib, nilotinib) 
 
 
prior treatment options 
still available 
 
question arises which 
therapy to choose 
 
reliable information is 
required to support 
choice of therapy 
mode of administration 
of a drug is important 
for patients 
 
oral administration 
preferred over i.v. 
administration 
Quality Appraisal of Written Consumer Health Information  
for Patients with Chronic Myeloid Leukaemia (CML) 
12 LBI-HTA | 2012 
1.3 Chronic Myeloid Leukaemia – Burden of 
Disease 
Leukaemia is a blood disorder, resulting from abnormal (not mature) white 
blood cells. Risk factors that are assumed to increase the risk of getting leu-
kaemia are exposition to certain chemicals, ionising radiation, cytostatics 
and genetic disposition [24]. Annually, about 12.5 per 100,000 habitants are 
diagnosed with leukaemia in the United States [25]. The classification of 
leukaemia depends mainly on the clinical course of the disease, maturity 
level and origin of the pathologically abnormal white blood cells. The two 
main differentiations are either chronic or acute leukaemia or lymphocytic 
or myeloid leukaemia. Thus, the four main types of leukaemia are acute 
myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL), chronic 
myeloid leukaemia (CML) and chronic lymphocytic leukaemia (CLL) [26]. 
CML is also known as chronic myelocytic, chronic myelogenous or chronic 
granulocytic leukaemia. It accounts for approximately 15% to 20% of all 
leukaemia cases and affects 1 to 2 persons per 100,000 habitants in the gen-
eral population. Median age at diagnosis is 50 to 60 years [27, 28]. CML can 
generally be divided into three phases: the chronic phase, the accelerated 
phase and the blast crisis. When diagnosed in the chronic phase and if left 
untreated, CML will progress to the accelerated phase and subsequently to 
the blast crisis, which inevitably ends fatally, over the course of 3 to 5 years 
[18]. Since the introduction of imatinib in newly diagnosed CML patients, 
the 5-year survival rate has increased substantially [18]. Approximately 85% 
of patients present a chronic phase of the disease and 20% to 50% are even 
asymptomatic at time of diagnosis [28]. Among patients diagnosed with 
symptomatic disease, systemic symptoms such as fatigue, malaise, weight 
loss, excessive sweating, abdominal fullness and bleeding episodes due to 
platelet dysfunction are commonly observed [28]. 
All patients suffering from CML demonstrate the fusion gene BCR-ABL 
[24] and >90% of CML patients have Philadelphia chromosome positive 
(Ph+) disease [29, 30]. The Philadelphia chromosome is generated by a re-
ciprocal translocation and fusion between the tyrosine kinase gene abelson 
(ABL) at chromosome 9 and the break-point cluster (BCR) gene at chromo-
some 22 and leads to altered cellular adhesion, activation of mitogenic sig-
nalling and inhibition of apoptosis and thereby to the transformation of he-
matopoietic stem cells. Ph+ cells are also referred to as BCR-ABL1 fusion 
genes [29]. The discovery of the Ph+ chromosome in 1960 and its tyrosine 
kinase activity has lead to the development of tyrosine kinase inhibitors 
(TKIs) in order to selectively inhibit the aberrant BCR-ABL tyrosine kinase 
and thus to significantly reduce the Ph+ CML cells [29]. 
Besides the three CML stages, the determination of risk scores also is of 
prognostic relevance and is important for the treatment management of 
CML patients [28, 30]. Two widely used scoring systems, the Sokal and the 
Hasford score, categorise patients into low-, intermediate- or high-risk pa-
tients. The Sokal score takes a patient’s age, spleen size, platelet counts and 
percentage of blast cells in the peripheral blood into account and was devel-
oped in patients receiving chemotherapy [30]. Additionally to the parame-
ters of the Sokal score, the Hasford score takes into account basophils and 
eosinophils. It was established based on data gathered from patients treated 
with interferon [28, 30]. 
leukaemia is a blood 
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1.4 Chronic Myeloid Leukaemia – Therapy 
Options 
In 2001, the first BCR-ABL TKI, imatinib mesylate (IM; Gleevec® / Glivec®) 
was approved by the European Medicines Agency (EMA) [31] and the US 
Food and Drug Administration (FDA) [32] for the treatment of CML [29] 
and has lead to improved 5-year survival rates [18]. Within the last 10 years, 
imatinib became the standard of care for the treatment of CML. In 2010, two 
further TKIs, nilotinib (Tasigna®) and dasatinib (Sprycel®), which demon-
strated promising results in clinical trials, were approved for first-line 
treatment of CML. All three TKIs have a category 1 recommendation as 
first-line agents for the treatment of CML in the chronic phase [30]. Long-
term follow-up data on efficacy and safety of the two new second-generation 
TKIs, nilotinib and dasatinib, are not yet available. Thus, their role in the 
first-line treatment of CML has not yet been finally established [30]. Cur-
rently, the stage of the disease, differences in the toxicity profiles of the 
three TKIs and BCR-ABL kinase domain mutation status of the disease are 
relevant for the choice of the potentially most effective TKI for a particular 
patient [19, 30]. There is one known mutation, T315I, all TKIs are resistant 
to. For patients with the T315I mutation, HSCT or enrolment into a clinical 
trial are the first-line therapies of choice. Further details about BCR-ABL 
kinase domain mutations and treatment recommendations are available in 
the National Comprehensive Cancer Network (NCCN) Clinical Practice 
Guideline [30] or in the recommendations for CML management by the 
European LeukemiaNet (ELN) [19]. 
For an effective treatment management, the response and resistance to TKI 
therapy have to be carefully monitored in order to switch to different ther-
apy options in case of treatment failure or suboptimal response. The three 
different response types monitored are hematologic, cytogenetic and mo-
lecular response with the goal to achieve complete hematologic response 
(CHR), complete cytogenetic response (CCyR), major molecular response 
(MMR) and complete molecular response (CMR) followed by each other in 
order of time [29, 30]. The ELN provides definitions of response to therapy 
and recommends the intervals depicted in Figure 1-1 for monitoring the re-
sponse [19]. 
 
Figure 1-1: Monitoring the response to imatinib according to the European 
LeukemiaNet Recommendations [19]  
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These intervals (Figure 1-1) are based on data collected in the course of 
imatinib treatments. As responses to nilotinib and dasatinib are more rapid, 
response testing is suggested to be done earlier and more frequently [19]. 
According to the NCCN guidelines, most patients who receive a TKI show 
complete hematologic response at 3 months and complete cytogenetic re-
sponse at 6, 12, or 18 months. In those patients who do not achieve hema-
tologic or cytogenetic response by these intervals, molecular analysis should 
be performed and the compliance of patients with the orally administered 
TKIs should be evaluated [30]. According to the ADAGIO (Adherence As-
sessment with Glivec: Indicators and Outcomes) study, adherence is the only 
independent predictive factor with regard to achieving complete molecular 
response [33]. Thus, patient education on adherence and appropriate man-
agement and monitoring of adverse events is recommended in order to help 
to improve patients’ adherence to therapy and thus effectiveness of therapy 
[30]. 
In patients who do not achieve a hematologic or cytogenetic response by the 
above mentioned intervals, switching to another second-generation TKI, 
HSCT or enrolment in a clinical trial should be considered [30]. Whereas 
HSCT is currently the only potentially curative therapy for CML, it is not 
recommended as initial therapy due to its substantial risk of mortality and 
late morbidity (e.g. graft-versus-host disease). HSCT is recommended when 
drug therapy failed or in patients in advanced stages of the disease [19, 30].  
1.5 Quality of Written Health Information 
Written consumer health information or patient information is available 
from different sources and different types such as brochures, flyers or web-
sites launched by various information providers. People interested in health 
information and access to the World Wide Web will face a wide variety of 
health information from different known and unknown sources and offered 
by various known and unknown information providers. Having access to all 
that information does not mean that those searching for information will 
find the information they require for their individual health question, as in-
formation provided may be sometimes incomplete, inaccurate and/or mis-
leading [15]. Potential reasons for this are that the information provider it-
self does not have the competences to create transparent and complete in-
formation materials or that the provider is simply more interested in con-
vincing the patient to opt for a certain product/health service rather than in 
providing unbiased, accurate and complete information as consumers would 
expect [34]. Thus, the key question remains which information materials pa-
tients can rely on and how to assure the quality of the provided information. 
“Quality” of written consumer health information can neither be described 
by one sentence, nor can one single description be valid for all the different 
types of consumer health information available. For example, the informa-
tion needs of patients who face the decision of whether to participate in a 
screening program or not are different from the information needs of pa-
tients diagnosed with a chronic, non-curable disease with several life-long 
treatment options [35]. One thing both cases have in common is that pa-
tients somehow have to make a decision: whether they want to participate in 
the screening program or which therapy option they would like to choose. 
This decision making process can be supported by discussion with health 
response evaluation is 
based on data collected 
with imatinib therapy … 
… questionable if these 
intervals are also valid in 
nilotinib or dasatinib 
therapy 
 
compliance might 
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therapy 
patients not responding 
to initial therapy should 
switch to another TKI, 
HSCT or be enrolled in a 
clinical trial 
various information 
providers produce 
various types of 
information materials 
 
availability and access to 
patient information 
does not necessarily 
mean that this 
information is of 
importance … 
… might be incomplete, 
inaccurate and/or 
misleading 
“quality” of a patient 
information material is 
highly dependent on the 
needs of the patients 
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care professionals and can also be complemented by high-quality written 
consumer health information. 
In 1998, Eysenbach and Diepgen published a paper discussing the “quality” 
of consumer health information. Referring to the International Organization 
for Standardization, Technical Committee 176 (ISO/TC 176), they defined 
“quality” as “the totality of characteristics of an entity that bear on its ability 
to satisfy stated and implied needs” [36]. Further, they state that, in order to 
evaluate the quality of health information on the internet, “these needs have 
to be defined and translated into a set of quantitatively and qualitatively 
stated requirements for the characteristics of an entity that reflect the stated 
and implied needs” [37]. 
Thereafter, international working groups have put an effort into translating 
this “need” into a set of criteria which can be used to define the quality of 
written consumer health information and have further developed several 
checklists for the quality assessment of written consumer health information 
(see chapter 1.6) [35]. A lot of research on the quality of health information 
is still ongoing in order to help health consumers distinguish trustworthy 
from non-trustworthy consumer health information [4, 6].  
In 2002, a policy paper on “Quality Criteria for Health related Websites”, a 
core set of quality criteria was developed and published by a working group 
initiated by the European Council within the initiative eEurope2002. Ac-
cording to this group, health-related websites have to meet several criteria in 
six different categories: transparency and honesty, authority, privacy and 
data protection, updating of information, accountability, accessibility [38]. A 
description of these six categories as provided by eEurope2002 is depicted in 
Figure 1-2.  
definition of the 
“quality” of consumer 
health information 
(CHI) 
criteria and checklists 
for assessing and 
determining the quality 
of CHI have been 
established 
quality criteria are 
grouped into different 
categories (e.g.: 
transparency and 
honesty, accountability, 
accessibility) 
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Figure 1-2: Quality criteria for health-related websites according to the policy paper by eEurope 2002 [38] 
Another European initiative, the Pharmaceutical Forum set up by the Euro-
pean Commission, also provided a set of core quality principles stating that 
patient information has to be objective and unbiased, patient-oriented, evi-
dence-based, up-to-date, reliable, understandable, accessible, transparent, 
relevant and consistent with statutory regulation of the EU member states 
[39]. In order to facilitate the implementation of these core principles in pa-
tient information materials and to prevent promotional orientation thereof, 
a guiding framework including clear and reproducible criteria for each prin-
ciple has been developed [40]. 
Other working-groups developed different sets of criteria to determine the 
quality of written consumer health information that generally addressed the 
questions of reliability of the information material and how good the infor-
mation was in terms of balanced presentation of benefits and harms, de-
scription of the intervention, natural course of disease or how the interven-
tion would affect a patient’s quality of life [15, 41]. Others again focused on 
assessing the authorship of the content, attribution to the sources of content, 
disclosure of sources of funding and competing interests and timeliness of 
information provided [34]. 
Although all of these initiatives created different sets of criteria, they have in 
common that they look at both, the so-called meta-information (authors, 
sponsor, financial dependence, aim of the publication, information sources, 
up-to-dateness of the information, statement of addresses for further infor-
mation on specific topics and support organisations) and the content of the 
information material (aim of the intervention, what would happen if the in-
a working group of the 
European Commission 
also defined a set of 
core quality principles 
overall, quality criteria 
address  
all initiatives look at 
meta-information 
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tervention was not given/refused, different treatment options, presentation 
of benefits and harms, etc.) [5].  
During the past decade, the term “evidence-based patient information 
(EBPI)” became more and more important [5, 6]. Proponents of EBPI claim 
that existing criteria for quality evaluation and supporting tools are not able 
to assess the quality of patient information, as their focus primarily lies on 
assessing the structure and meta-information of information materials 
rather than on assessing the accuracy of information, way of presentation of 
the information or development process of the materials [5]. For example, 
EBPI looks at the way risks are communicated to patients – are they solely 
shown as words/numbers within the text or are risks shown as graphical il-
lustrations and, if yes, are relative or absolute risks presented [42, 43]. Fur-
ther, it is looked at the “reading ease” – is the level of the language used ap-
propriately chosen for the target group defined upfront? Other questions fo-
cus on the level of the evidence used to develop the health information ma-
terial – is it explicitly stated? Does the information tell us what we do not 
yet know and are the benefits and risks balanced and accurate? On the other 
hand, there is not yet certainty about what can be expected of EBPI. Thus, 
Steckelberg et al. (2005) [5] and Bunge et al. (2010) [6] conducted a system-
atic review on quality criteria for EBPI and suggest the following pool of 
categories as essential quality criteria for EBPI: 
1. Content of information and meta-information 
2. Quality of evidence 
3. Patient-oriented outcome measures 
4. Presentation of numerical data 
5. Verbal presentation of risks 
6. Diagrams, graphics and charts 
7. Gain and loss framing 
8. Pictures and drawings 
9. Patient narratives 
10. Cultural aspects 
11. Layout 
12. Language 
13. Development process 
The authors referred to above summarize that gathering these categories was 
a first step in defining EBPI. Some of these categories are supported by 
high-evidence level literature and some of them lack high-evidence level re-
search. For now, this set of criteria can be used as a guide for developers of 
EBPI. Future research in this field could focus on conducting studies that 
fill the gaps in high-level evidence and to develop a comprehensive guide to 
develop EBPI and a validated instrument for assessing EBPI [44]. 
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1.6 Quality Assessment of Written Health 
Information 
Generally, there are several possible ways of how to assess the quality or 
trustworthiness of consumer health information. The easiest and less time-
consuming way is to rely on codes of conducts, so called quality labels, seals 
or logos such as Health on the Net (HON), “Aktionsforum Gesundheitsin-
formationssysteme” (AFGIS) or “The Information Standard”. These codes of 
conducts have been developed by third-party organisations and are aimed to 
set apart trustworthy from non-trustworthy information sources [35, 38, 45-
48]. Owners of websites can apply for these certifications. If they are compli-
ant with the predefined criteria, the owners of the websites are allowed to 
put the corresponding quality logo on their website for a certain period of 
time after which they have to apply for re-examination by the third-party 
organisation in order to keep the certification up-to-date. But the mere 
availability of a quality seal on a website does not necessarily mean that the 
website has been approved by the provider of the quality seal. Thus, it is ad-
visable to click on the logo, which is active when approved and links to the 
provider of the quality label. There, consumers have access to the informa-
tion whether the certification is up-to-date and when the certification will 
expire. For example, a click on an active HON label opens a new page where 
details such as first HON approval, renewal of approval and approval dura-
tion or re-examination status are listed. This service enables health consum-
ers to check whether the site displaying the quality seal is compliant with 
the quality criteria of the label or not [38]. Tools like HON or AFGIS have 
been developed as quality labels and give consumers hints about the trust-
worthiness of the website. In this connection, the criteria for the certification 
consider solely the structural quality of the information provider, but not 
the content of the website [35, 38].  
Another, more sophisticated approach to assess the quality of consumer 
health or patient information is to use tools or checklists developed to assess 
the quality of written consumer health information [5, 6, 35, 49]. These 
checklists can either be used as a guide for the development of health infor-
mation or to assess existing information by health consumers themselves or 
by scientists for research purposes. Despite the existence of multiple tools 
and criteria, there is no generally accepted gold standard defined for the ap-
praisal of the quality of written consumer health information [35]. 
To give an overview of the variety of the available instruments, some of them 
are briefly described below with their main characteristics: 
DISCERN was the first standardised and validated instrument that was de-
veloped for the quality appraisal of written consumer health information. It 
enables consumers and information providers to assess the structural quality 
of written consumer health information on different treatment choices [15, 
35]. 
Check-In was developed based on DISCERN and AGREE (a checklist de-
veloped to assess the quality of clinical guidelines [50]) by a group of re-
searchers in Germany to provide a tool for the quality assessment of printed 
or electronic health information in terms of their ability to be a decision aid 
for users/consumers [41]. The Check-In instrument is currently not vali-
dated or published, but can be accessed and downloaded online (via 
several approaches to 
assess the quality of 
written patient 
information (e.g. quality 
labels or codes of 
conducts such as HON) 
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http://www.patienten-information.de/patientenbeteiligung/ 
check_in.pdf/view) [35]. 
IPDASi is a validated instrument developed in a comprehensive process by 
an international team of researchers, the International Patient Decision Aids 
Standards Collaboration (IPDAS), to assess the quality of patient decision 
aids and to support and help developers of decision aids to produce high-
quality patient decision aids [51]. 
IPDASi is the most recently developed and validated tool for the quality as-
sessment of patient decision aids. Decision aids are defined as “interven-
tions designed to help people make specific and deliberative choices among 
options by providing information about the options and outcomes that is 
relevant to a person’s health status” [52]. The aim of this study was to assess 
the quality of patient information on CML and its treatment options in gen-
eral and not specifically of decision aids. 
For the above reasons, the quality of the included printed or online written 
consumer health information on CML and its treatment options will be as-
sessed using the standardised quality appraisal instrument DISCERN [15]. 
 
IPDASi: validated 
instrument to assess the 
quality of patient 
decision aids 
focus of this study is on 
the quality of patient 
information, thus 
DISCERN was chosen 
for quality assessment 
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2 Research Question and Aim  
The aim of this study is to appraise the quality of written patient informa-
tion materials about CML and its treatment options by using a standardised 
quality appraisal instrument and thereby identify areas for improvement. 
Further, the study will investigate whether there are differences in the qual-
ity of information materials provided by organisations that were actively 
seeking a quality certification for their organisation themselves compared to 
those which do not display a quality label on their website. 
 
aim of the study: 
assessment of the 
quality of written 
patient information for 
CML 
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3 Methods 
3.1 Identification of Materials: Search 
Strategy 
To find written consumer health information materials about CML, we con-
ducted an internet search in three search engines (www.google.com, 
www.yahoo.com, www.bing.com) [48]. We were looking for written con-
sumer health materials about the treatment of CML including information 
on at least one of the three TKIs approved for CML therapy. Since not all 
patients and their relatives are familiar with sophisticated search mecha-
nisms like Boolean operators [53] and since search engines do not have the 
capacity for complex searches as databases like Medline or Embase, we de-
cided not to use the above instruments but rather search with single words to 
imitate the search behaviour of patients. Although we generally assume that 
patients would search with terms related to the indication (e.g. leukaemia, 
CML) we decided to use the names of the currently approved TKIs to ensure 
to get information about treatment options for CML rather than only about 
the disease in general. As already pointed out in the introduction, two new 
TKIs have been approved by the end of 2010. Thus, there are two additional 
orally administered and targeted drugs available for the treatment of CML 
patients which are considered to play an essential role in the treatment of 
CML. Therefore, we assume that the new drugs have already been included 
in existing patient information. As such, the search terms we used were the 
generic and brand names of these three drugs – imatinib, glivec®, dasatinib, 
sprycel®, nilotinib and tasigna®. The search within the three search engines 
was conducted between May 25, 2011 and June 04, 2011. 
Studies show that 62% of search engine users click on a link displayed on 
the first page of the search results and 90% of search engine users consider 
only the search results of the first three pages [54, 55]. Nevertheless, we 
screened the first 100 hits for each search to make sure we did not miss any 
relevant information materials. As a first step, we copied the URL of web-
sites containing information on CML and its treatment options in a spread-
sheet with further information regarding date of publication or last update 
and name of the information provider. In a second step, we had a closer look 
at the gathered links to check whether they met our predefined inclusion 
criteria (see paragraph below) and included or excluded them for quality as-
sessment. All in all, the search in three search engines with six different 
terms resulted in 1800 hits to be screened. 
In addition, the marketing authorisation holders for the three TKIs, as well 
as national and European umbrella organisations of patient organisations 
and medical societies related to leukaemia were contacted directly and asked 
to send their patient information material related to the treatment of CML. 
Furthermore, between June 06, 2011 and June 28, 2011, we screened the 
websites of these 118 institutions for patient information materials meeting 
our inclusion criteria (Appendix, Table 10-1). Throughout the following 
pages, the first part of the search strategy will be referred to as internet 
search or websearch (WS) and the second part as handsearch (HS). 
The study included written consumer health information available through 
internet websites or upon request by various institutions that: 
internet search in three 
widely used search 
engines: Google, Yahoo 
and Bing 
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 were specifically written for patients and lay audience, 
 provide background information on CML, 
 refer to different (at least one) therapy options for CML and 
 were either in German or English. 
Books, newspaper articles, scientific articles, package inserts/prescribing in-
formation, approval information, video tapes and discussion boards/forums 
were excluded. 
3.2 Quality Assessment – DISCERN 
Instrument 
DISCERN was the first instrument developed to help health consumers and 
information providers assess the quality of written information about differ-
ent treatment choices for a health problem [15, 56]. The validated [57] rat-
ing tool is freely available in the internet and a handbook describing the use 
of DISCERN is provided at www.discern.org.uk. DISCERN consists of 16 
questions divided into three different sections: section 1 (questions 1-8) fo-
cuses on the reliability of the patient information material and section 2 
(questions 9-15) evaluates the quality of the information of the different 
treatment options described. The third section (question 16) asks for an 
overall quality rating of the source as a whole and its potential to be an ap-
propriate source of information for supporting decision making about the 
treatment options for the patient after having rated the first 15 questions 
[58]. Each DISCERN item was rated based on a 5-point rating scale ranging 
from definitively no (rating: 1) to definitively yes (rating: 5) according to the 
description in the DISCERN handbook [49, 58]. The intervals between the 
ratings are assumed to be of the same interval / evenly distributed. The 
DISCERN rating was conducted by two independent assessors. Disagree-
ment was resolved by discussion. For statistical analysis and comparison of 
the included materials either the absolute DISCERN rating (minimum 15 to 
maximum 75) or the means of the DISCERN rating, later on referred to as 
DISCERN score, of section 1 and 2 (questions 1 to 15; minimum 1 to maxi-
mum 5) were used. For further description of the quality of the included ma-
terials, the DISCERN rating was divided into five categories: excellent (63-
75), good (51-62), fair (39-50), poor (27-38) and very poor (15-26) [57].  
In addition to the DISCERN questions, we extracted further descriptive 
data related to the information provider (e.g. type of organisation, funding 
of organisation, availability of quality labels such as “Health on the Net” 
(HON) or AFGIS (www.hon.ch, www.afgis.de) [5]) and type and publication 
date of the information material for further characterization of the included 
materials. The study protocol was approved by the Research Committee for 
Scientific and Ethical Questions (RCSEQ) at UMIT – University for Health 
Sciences, Medical Informatics and Technology and at fhg – Fachhochschule 
Gesundheit GmbH [59]. 
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3.3 Statistical Analysis 
The final number of included materials was not known a priori. Hence, no a-
priori hypotheses were generated. Thus, this study is primarily exploratory 
and aims to generate hypotheses to be investigated in further and more ex-
tensive studies. Although the 5-point rating-scale is not an interval scale per 
definition, we assumed that the intervals between the 5 points were equal. 
Therefore, we calculate means and standard deviations (SD) for the descrip-
tive analyses based on the DISCERN ratings. To quantify the variation of 
standard deviation, the coefficient of variation was computed. A mean DIS-
CERN score (minimum 1 to maximum 5) was calculated by averaging the 
ratings of question 1 to 15 (DISCERN sections 1 and 2) to compare the rat-
ings of the materials by their specific characteristics. The distribution of the 
data was examined using the histogram (Appendix, Figure 10-1). As normal 
distribution of the data was not shown and the number of included materials 
was small, non-parametric tests were performed for comparison. Depending 
on the amount of groups for comparison, either the Mann-Whitney U test or 
the Kruskal-Wallis test [60] was used to compare the mean DISCERN scores 
based on the following categories: information providers, availability of 
quality labels and the amount of quality labels available, primary source of 
funding, language and publication date of the included materials. For 
graphical illustration of the results we used a point diagram, a pie chart and 
a histogram. Results of the statistical tests were considered significant at 
p<0.05. The analyses were conducted using SPSS version 18. 
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4 Results 
4.1 Selection of Written Consumer Health 
Information for Quality Assessment 
After the initial websearch, 516 links referring to CML and to at least one 
treatment option for CML were included to be examined in detail. The exact 
list of URLs including source of information search and reason for exclusion 
can be obtained from the authors. Of these 516 hits, 15 fulfilled the inclu-
sion criteria and were included for quality assessment. 
Of the 118 institutions we contacted (Appendix, Table 10-1), 18 (15.3%) re-
sponded to our request for information. The organisations that responded to 
our e-mail asking for written consumer health information were charities, 
patient organisations and scientific groups. These organisations responded 
within a time period of 1 to 10 days. Eight materials of these 18 institutions 
were included for quality assessment, the remaining 10 were excluded be-
cause they did not provide patient information at all or on CML (n=8) or 
the language was other than English or German (n=2; Dutch, Serbian). 
Upon searching the websites of these institutions, 24 patient information 
materials were identified; 7 of those were duplicates of the materials sent to 
us upon our e-mail request. Thus, 25 references of 20 different institutions 
were included based on the second part of the search strategy. 8 of the 25 
hits of this handsearch were duplicates of materials already obtained by the 
websearch. 
Combining these two search strategies, 33 patient information materials by 
29 different organisations were included for quality assessment. Some of 
these institutions provided more than one information material for patients 
(e.g. leaflet and brochure or brochure and website). The flow-chart illustrat-
ing the search and reasons for exclusion is depicted in detail in Figure 4-1.  
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Figure 4-1: Selection process of written CHI materials on CML for the quality assessment with the standardized instrument DISCERN 
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4.2 Overall Characteristics of Included 
Information Materials 
The list of the 33 included patient information materials on CML and its 
treatment options is available in Table 4-1. The identification number of the 
included materials provided in the first column of Table 4-1 will be used for 
identifying the materials within tables and figures. 22 materials were written 
in English and 11 materials were in German. The materials were either 
hard-copy brochures (n=4) directly sent to us via mail by the referring pro-
vider, PDFs (n=7) downloaded from the websites of providers or by follow-
ing the link sent to us via e-mail by providers or (sub-)websites (n=22) of in-
formation providers. Some of the PDFs are actually printed information 
brochures for patients, but the organisations could not send them to us via 
mail, as they are either not allowed to send information material outside 
their country of residence due to individual institutional guidelines or be-
cause they sent the wrong brochure or the organisations did not respond to 
our e-mail asking to provide hard copies of their brochures at all. 
All included materials were published or updated between 2006 and 2011. In 
the case of 9 materials, we could not find information about the publication 
date, 8 were published between 2006 and 2009 and the remaining 16 refer-
ences were published 2010 or 2011.  
description of the 
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Table 4-1: Included patient information materials in alphabetical order of the information providers 
ID Title of the Information Material 
Pub-
lication 
Date 
Type of In-
formation ma-
terial 
Language Information Provider / Name of Organisation Weblink 
HS_E_1 Leukemia -- Chronic Myeloid (Myelogenous) 2011 PDF English American Cancer Society http://www.cancer.org/acs/groups/cid/documents/webcontent/003112-pdf.pdf  
WS_B_2 Chronische Myeloische Leuka¨mie 2011 Website German 
Apotheken-Umschau; 
Medikamentencheck 
Arzneimittelinformationen 
http://www.apotheken-
umschau.de/leukaemie/cml  
WS_G_3 What is chronic myeloid leukemia (CML)? 2011 Website English Bristol Mayer Squibb http://www.sprycel.com  
WS_G_4 Chronic myeloid leukaemia (CML) 2010 Website English Cancer Research UK http://cancerhelp.cancerresearchuk.org/type/cml 
HS_W_5 Leukemia - Chronic Myeloid – CML 2010 Website English Cancer.Net http://www.cancer.net/patient/Cancer+Types/Leukemia+-+Chronic+Myeloid+-+CML  
HS_W_6 Leben mit chronisch myeloischer Leuka¨mie (CML) NA PDF (w) German Central European Leukemia Study Group (CELSG) 
http://www.cml-
info.com/fileadmin/pictures/Downloads/CML
_Brosch%FCre.pdf  
HS_W_7 Die chronische myeloische Leuka¨mie im U¨berblick NA Website (PDF) German 
Central European Leukemia 
Study Group (CELSG) 
http://www.cml-info.com/de/patienten-und-
betroffene/die-cml-im-ueberblick.html  
HS_W_8 Novartis Oncology - Information on Chronic Mye-loid Leukemia (CML) 2007 Website English CML Alliance 
http://www.novartisoncology.com/patients-
caregivers/what-is-cancer/chronic-myeloid-
leukemia.jsp  
HS_W_9 Leuka¨mie bei Erwachsenen. Die blauen Ratgeber. Antworten. Hilfen. Perspektiven 2011 Brochure German Deutsche Krebshilfe e.V. 
http://www.krebshilfe.de/fileadmin/Inhalte/
Downloads/PDFs/Blaue_Ratgeber/020_leuka
emie.pdf  
WS_B_10 Chronische Myeloische Leuka¨mie - Ratgeber fu¨r Patienten 2010 Brochure German 
Deutsche Leuka¨mie- & 
Lymphomhilfe e.V. (DLH) 
http://www.leukaemie-
hil-
fe.de/broschueren.html?&no_cache=1&tx_dr
blob_pi1[downloadUid]=78  
HS_W_11 Krebsarten: Leuka¨mien und Lymphome – Leuka¨-mie 2011 Website German 
Deutsche Krebsgesellschaft 
(DKG) 
http://www.krebsgesellschaft.de/pat_ka_leu
kaemie_therapie_chronische,107827.html  
HS_E_12 Chronic Myeloid Leukaemia (CML) 2011 Website English 
Irish Cancer Society - The 
national charity for cancer 
care 
http://www.cancer.ie/cancerInfo/cml_cancer
_information.php  
HS_W_13 Informationen fu¨r Patienten 2008 Website German Kompetenznetz Leuka¨mien http://www.kompetenznetz-leukaemie.de/content/patienten  
HS_E_14 Leuka¨mie bei Erwachsenen. Eine Information der Krebsliga fu¨r Betroffene und Angeho¨rige 2008 PDF German Krebsliga Schweiz http://assets.krebsliga.ch/downloads/1025.pdf  
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ID Title of the Information Material 
Pub-
lication 
Date 
Type of In-
formation ma-
terial 
Language Information Provider / Name of Organisation Weblink 
HS_W_15 Chronic Myeloid Leukaemia (CML) 2010 PDF (w + PDF) English 
Leukaemia & Lymphoma 
Research 
http://www.beatbloodcancers.org/sites/defa
ult/files/CML%20booklet_0.pdf  
HS_W_16 Chronic Myeloid Leukaemia (CML) NA PDF (w + PDF) English 
Leukaemia & Lymphoma 
Research 
http://www.beatbloodcancers.org/sites/defa
ult/files/CML%20leaflet_0.pdf  
HS_W_17 Chronic myeloid leukaemia (CML) 2011 Website (2 PDF) English 
Leukaemia & Lymphoma 
Research 
http://leukaemialymphomaresearch.org.uk/p
atient-information/chronic-myeloid-
leukaemia-cml  
HS_W_18 Chronic Myelogenous Leukemia NA PDF (w) English 
Leukemia & Lymphoma So-
ciety - fighting blood can-
cers 
http://www.lls.org/content/nationalcontent/
resourcecen-
ter/freeeducationmaterials/leukemia/pdf/cml
.pdf  
HS_W_19 Leukemia - Chronic Myeloid Leukemia 2011 Website (PDF) English 
Leukemia & Lymphoma So-
ciety - fighting blood can-
cers 
http://www.lls.org/#/diseaseinformation/leu
kemia/chronicmyeloidleukemia  
WS_B_20 Das Special: CML 2008 Website German 
Lifeline - Gesundheitsportal 
von Springer Medizin; 
BSMO GmbH 
http://www.lifeline.de/cda/krankheiten_a-
z/krankheitenlexikon/content-137653.html#C  
WS_G_21 Chronic Myeloid Leukaemia 2011 Website English Macmillan 
http://www.macmillan.org.uk/Cancerinform
ation/Cancertypes/Leukaemiachronicmyeloid
/CML.aspx  
HS_W_22 Chronic Myelogenous Leukemia 2010 Website English Mayo Clinic http://www.mayoclinic.com/health/chronic-myelogenous-leukemia/DS00564  
WS_G_23 My CMLCircle® - Building around you. About CML NA Website English 
MyCMLCircle® - Novartis 
Oncology 
http://www.mycmlcircle.com/patient/tasigna
-side-
ef-
fects.jsp?usertrack.filter_applied=true&Nova
Id=2935376878981282949  
WS_G_24 What You Need to Know About™ Leukemia 2008 Brochure English National Cancer Institute  http://www.cancer.gov/cancertopics/wyntk/leukemia.pdf  
HS_W_25 Living with CML 2010 Website English National CML Society http://nationalcmlsociety.org/how-use-our-site  
WS_G_26 Chronic Myelogenous Leukemia (CML), Imatinib (Gleevec®) and Transplant NA Website English 
National Marrow Donor 
Program (NMDP) 
http://www.marrow.org/PATIENT/Undrstnd
_Disease_Treat/Lrn_about_Disease/CML/inde
x.html  
WS_G_27 Nilotinib Information NA Website English Nilotinib.org http://www.nilotinib.org  
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ID Title of the Information Material 
Pub-
lication 
Date 
Type of In-
formation ma-
terial 
Language Information Provider / Name of Organisation Weblink 
WS_G_28 CML - Chronische Myeloische Leuka¨mie NA Website German Novartis Pharma Schweiz 
http://www.cml-
info.ch/page/content/index.asp?MenuID=531
8&ID=9649&Menu=51&Item=18  
WS_G_29 Chronic Myeloid Leukaemia 2006 Website English Patient.co.uk http://www.patient.co.uk/health/Leukaemia-Chronic-Myeloid.htm  
WS_Y_30 Leukemia - Health Pages 2008 Website English Revolution health http://www.revolutionhealth.com/conditions/cancer/leukemia/index  
HS_E_31 CML - Chronische Myeloische Leuka¨mie. Ein Rat-geber fu¨r Patienten und Angeho¨rige NA Brochure German 
Stiftung zur Fo¨rderung der 
Knochenmarktrans-
plantation (SFK) 
www.knochenmark.ch   
WS_G_32 
Imatinib for chronic myeloid leukaemia. Under-
standing NICE guidance - information for people 
with CML, their families and carers, and the public 
2011 PDF English UK NICE http://www.nice.org.uk/nicemedia/live/11516/32755/32755.pdf  
WS_G_33 Chronic myelogenous leukemia 2006 Website English Wrongdiagnosis.com http://www.wrongdiagnosis.com/c/chronic_myelogenous_leukemia/intro.htm  
Abbreviations: NA – not available; ID – identification number of the material: is a combination of source of search (WS – websearch or HS – handsearch) and a consecutive number from 1-33 of 
the materials in alphabetical order of the information provider: WS_G/Y/B – websearch in Google/Yahoo/Bing; HS_E/W – handsearch + material retrieved either via e-mail or website. 
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18 of the 33 materials were from information providers that displayed the 
logo of a quality certification on their website. The amount of quality labels 
at the websites of information providers ranged from 0 to 4. 8 websites had 1 
quality label, 6 websites had 2, 3 had 3 and 1 had 4 different quality labels. 
All in all, 14 different quality labels were identified. These quality labels are 
depicted in Table 4-2 and a brief piece of information about the organisa-
tions managing these certificates including their aims is provided. 
Providers of the patient information materials were charities (n=8), scien-
tific groups (n=5), public institutions (n=2), pharmaceutical industry 
(n=4), patient organisations (n=4), health organisations (n=4), other com-
mercial organisations (n=5) and others (n=1).  
Primary source of funding of these information providers is a mix of funding 
(n=13), industry (n=9), public funding (n=2), donations from individuals 
(n=4) and for 5 information providers, no information regarding funding 
was accessible via the internet. For the purpose of analysing the differences 
in means, the above-mentioned providers of health information were 
grouped into three different categories (non-profit organisations, commer-
cial organisations and others) due to the small number of included materials 
per information provider. 
18 materials were from 
information providers 
that had a quality 
certification 
providers of information 
materials 
primary source of 
funding of the 
providers: mix of 
funding, industry, public 
funding and donations 
from individuals 
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Table 4-2: Overview of quality labels displayed on the websites of the information providers of the included 
materials 
 
Quality Label Name of the Organisa-tion Logo / Label 
Aim of the Organisation 
and Quality Certification Weblink 
AFGIS 
Aktionsforum Gesund-
heitsinforma-
tionssystem e.V. 
Promotes the quality of 
health information.  http://www.afgis.de  
AMRC Association of Medical Research Charities  
Aims to support the medi-
cal research sector’s effec-
tiveness and advanced 
medical research by devel-
oping best practice, provid-
ing information and guid-
ance, improving public dia-
logue about research and 
science, and influencing 
government. 
http://www.amrc.org
.uk/home  
Charity Navi-
gator 
Charity Navigator – 
Your Guide To Intelli-
gent Giving  
The goal is to help people 
to donate to charities with 
confidence and to aim to 
help charities by shining 
lights on truly effective or-
ganizations. 
http://www.charityna
vigator.org  
FRSB Fund Raising Standards Board 
 
Oversees a transparent and 
independent regulatory 
scheme for fundraising, 
aiming to raise standards 
and build public confidence 
in fundraising. 
http://www.frsb.org.
uk  
GuideStar® 
Member Guide Star  
GuideStar encourages non-
profit organisations to 
share information about 
their organisation openly 
and completely. 
http://www2.guidest
ar.org  
HON Health on the Net Foundation 
 
Promotes and guides the 
development of useful and 
reliable online health in-
forma-tion, and its appro-
priate and efficient use. 
http://www.hon.ch  
MediSuch 
MediSuch. Die Spezial-
Suchmaschine fu¨r Me-
dizin und Gesundheit 
 
MediSuch is a search en-
gine in the field of medi-
cine and health that 
searches within a positive 
list of information provid-
ers who are independent 
from the related industry. 
http://www.medisuch
.de  
SHQA Swiss Health Quality Association 
 
Aims to promote the qual-
ity of information and 
communication in the 
health care sector. 
http://www.shqa.ch/i
ndex.cfm  
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Quality Label Name of the Organisa-tion Logo / Label 
Aim of the Organisation 
and Quality Certification Weblink 
Standards of 
Excellence® 
Standards of Excellence 
Certification Program 
of the National Health 
Council 
 
Is a set of good operating 
practices to ensure that 
the voluntary health 
agency members of the 
National Health Council 
maintain the highest stan-
dards of organizational ef-
fectiveness and public 
stewardship. 
http://www.national
healthcoun-
cil.org/pages/standar
ds.php 
Stiftung Ge-
sundheit – 
Zertifizierte 
Website 
Stiftung Gesundheit 
 
The aim of Stiftung Ge-
sundheit is to foster trans-
parency and to offer prac-
tical guidance within the 
health care sector. 
http://www.stiftung-
gesundheit.de  
The Crystal 
Mark Stan-
dard 
Plain English Campaign 
– Fighting for crystal-
clear communication 
since 1979 
Aims to assess the clarity 
of documents – it is given 
if publicly available infor-
mation is provided as clear 
as possible. 
http://www.plainengl
ish.co.uk/crystal-
mark/about-the-
crystal-mark/the-
crystal-mark-
standard.html  
The Informa-
tion Standard 
The Information Stan-
dard developed by the 
Department of Health, 
UK  
Aims to help the public 
identify trustworthy 
health and social care in-
formation easily. 
http://www.theinfor
mationstandard.org  
VKI-
Konsument.at 
Verein fu¨r Konsum-
enteninformation 
(VKI) (registered asso-
ciation for con-sumer 
information) 
VKI advocates the interests 
of the Austrian consumers, 
informs them about and 
supports them in enforcing 
their rights. 
http://www.konsume
nt.at/cs/Satellite?pag
ename=Konsument/
MagazinAr-
tikel/Detail&cid=3188
70962529  
ZEWO 
Schweizerische Zertifi-
zierungsstelle fu¨r ge-
meinnu¨tzige, Spenden 
sammelnde Organisati-
onen  
Takes a stand for the pro-
motion of transparency 
and integrity in the field of 
donations and audits non-
profit organisations in 
terms of faithful handling 
of the received donations. 
http://www.zewo.ch  
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4.3 Overall DISCERN Results 
The overall mean DISCERN rating of a maximum rating of 75 points based 
on the questions 1 to 15 is 44.12 (range 24 to 65; SD 11.49) across all in-
cluded information materials. The overall mean DISCERN score is 2.94 
(range 1.6 to 4.33; SD 0.766) out of a maximum score of 5 across all included 
materials. The mean score, range and SD for each DISCERN question are 
shown in Table 4-3, ranging from 1.64 (SD 1.14; description of what would 
happen if no treatment is used) to 4.36 (SD 0.93; make clear that more than 
one treatment option is available).  
Table 4-3: Combined results of the sixteen DISCERN questions based on all 33 information materials 
DISCERN Question Mean Score SD CV 
Minimum 
Score 
Maximum 
Score 
1. Is the publication reliable? 3.39 1.41 0.42 1 5 
2. Does it achieve its aims? 3.85 1.30 0.34 1 5 
3. Is it relevant? 3.91 1.16 0.30 2 5 
4. Is it clear what sources of information were used 
to compile the publication (other than the author or 
producer)? 
2.15 1.46 0.68 1 5 
5. Is it clear when the information used or reported 
in the publication was produced? 2.03 1.72 0.85 1 5 
6. Is it balanced and unbiased? 3.48 1.23 0.35 1 5 
7. Does it provide details of additional sources of sup-
port and information? 3.09 1.51 0.49 1 5 
8. Does it refer to areas of uncertainty? 2.00 0.75 0.38 1 4 
9. Does it describe how each treatment works? 3.12 1.47 0.47 1 5 
10. Does it describe the benefits of each treatment? 2.97 1.08 0.36 1 5 
11. Does it describe the risks of each treatment? 2.91 1.26 0.43 1 5 
12. Does it describe what would happen if no treat-
ment is used? 1.64 1.41 0.86 1 5 
13. Does it describe how the treatment choices affect 
overall quality of life? 2.45 0.87 0.36 1 4 
14. Is it clear that there may be more than one possi-
ble treatment choice? 4.36 0.93 0.21 1 5 
15. Does it provide support for shared decision-
making? 2.76 1.17 0.42 1 5 
16. Overall rating of the quality of the publication as 
a source of information about treatment choices on 
the previous answers 
2.70 0.85 0.31 1 4 
Abbreviations: SD – standard deviation; CV – coefficient of variation 
 
mean DISCERN rating: 
44.12 (range 24 to 65) 
 
mean DISCERN score: 
2.94 (range 1.6 to 4.33) 
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Taking the coefficient of variation into account, question 5 “Is it clear when 
the information used or reported in the publication was produced?” and 
question 12 “Does it describe what would happen if no treatment is used?” 
demonstrate a high variation of the DISCERN rating, 0.85 and 0.86, respec-
tively. On the other hand, question 14 “Is it clear that there may be more 
than one possible treatment choice?” shows a rather small variation with a 
coefficient of variation of 0.21. 
DISCERN question 16 aks for an overall rating of the relevance of the 
publication as a source of information about treatment choices. As shown in 
Figure 4-2, none of the included materials was considered to be a complete, 
accurate and comprehensive source of information about treatment choices 
or an aid for decision making. Three were regarded as being definitely no 
appropriate materials for information and the majority of included materials 
are considered to be partly appropriate. 
Figure 4-2: Overall rating (DISCERN question 16) of the information material 
as a source for information about treatment options 
Table 4-4 gives an overview of the DISCERN ratings represented as the five 
predefined categories (excellent, good, fair, poor and very poor) of the in-
cluded materials depicted according to the information providers. 2 materi-
als are rated as excellent information materials, 7 and 12 were considered to 
be good and fair, respectively, and 12 materials were rated as poor or very 
poor information materials.  
 
 
 
 
 
the majority of included 
materials were 
considered partly 
relevant as a source of 
information about 
treatment choices 
2 and 12 materials were 
considered being 
excellent and poor or 
very poor, respectively 
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Table 4-4: Information materials according to categories of DISCERN ratings and information provider 
 Charity 
(n=8) 
Scientific 
Group 
(n=5) 
Public Institu-
tion 
(n=2) 
Pharma In-
dustry 
(n=4) 
Patient 
Org. 
(n=4) 
Health 
Org. 
(n=4) 
Other Com-
mercial Org. 
(n=5) 
Others 
(n=1) 
Excellent 
(63-75) 1 - - - 1 - - - 
Good 
(51-62) 2 3 1 - 1 - - - 
Fair 
(39-50) 2 2 - 1 1 4 2 - 
Poor 
(27-38) 2 - 1 3 1 - 3 1 
Very poor 
(15-26) 1 - - - - - - - 
Abbreviation: Org - Organisation 
4.4 DISCERN Score According to 
Characteristics of Information Materials 
In order to find parameters that might influence or have an impact on the 
quality of written consumer health information, we performed analyses con-
sidering the different characteristics of the included patient information ma-
terials or the corresponding provider. 
Figure 4-3 illustrates the heterogeneity of the included materials in terms of 
DISCERN rating of each included information material according to the 
categories non-profit organisations, commercial organisation or others re-
lated to the provider of the information material. 
The means of DISCERN ratings showed a statistically significant discrep-
ancy between these 3 types of information providers (p=0.012) with non-
profit organisations having the highest values and commercial organisations 
having the lowest values. The mean scores range from 3.22 (SD 0.725; non-
profit organisation) to 2.84 (SD 0.65; others). The same was observed when 
comparing the ratings of German-language and English-language materials, 
with a higher mean DISCERN score for English-language information ma-
terial (p=0.031) (Table 4-5). 
characteristics of 
materials that might 
impact the quality of 
patient information 
materials 
statistically significant 
difference in mean 
DISCERN score 
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Figure 4-3: DISCERN rating (min 15 to max 75) based on questions 1 to 15 
according to type of information provider 
The comparison by the primary source of funding of the information pro-
vider was statistically significant (p=0.020). Those organisations that were 
primarily financed by a mix of funding had the highest DISCERN score 
compared to those solely financed by industry or those who did not provide 
information about their funding at all. 
In contrast, the comparison of information providers that were approved by 
a quality seal and the amount of quality labels available did not show any 
statistically significant differences. The same is true for the comparison by 
type of information material (brochure, PDF or website) and publication 
date of the material.  
 
 
difference in quality 
rating according to 
primary source of 
funding 
mean DISCERN score 
did not differ 
statistically significant 
between providers that 
had a quality 
certification 
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Table 4-5: Comparison of the mean DISCERN score by characteristics of the information materials 
Characteristics (n) 
Mean 
DISCERN 
score 
SD Mean DISCERN rating of max 75 SD p value* 
Overall (33) 2.94 0.77 44.12 11.49 
     
Type of Information Provider     
 
Non-Profit Organisations (21) 3.22 0.73 48.29 10.88 
Commercial Organisations (9) 2.33 0.54 34.89 8.15 
Others (3) 2.84 0.65 42.67 9.82 
0.012 
     
Primary Source of Funding     
 
Mix of Funding (13) 3.44 0.65 51.62 9.69 
Industry/Commercial (9) 2.33 0.54 34.89 8.15 
Public Funding (2) 3.03 0.80 45.50 12.02 
Donations of Individuals (4) 2.65 0.90 39.75 13.53 
Not available (5) 2.95 0.58 44.20 8.64 
0.020 
     
Quality Label available     
 
Yes (18) 3.03 0.77 45.50 11.55 
No (15) 2.83 0.77 42.47 11.61 
0.385 
     
Number of Quality Labels     
 
1 label (8) 2.56 0.52 38.38 7.84 
2 labels (6) 3.68 0.63 55.17 9.52 
3 labels (3) 2.76 0.72 41.33 10.79 
4 labels (1) 3.8 - 57 - 
None (15) 2.83 0.77 42.47 11.61 
0.055# 
     
Type of Information Material     
 
Brochure (4) 3.68 0.48 55.25 7.18 
PDF (7) 2.97 0.95 44.57 14.27 
Website (22) 2.78 0.69 41.95 10.35 
0.123 
     
Language     
 
German (11) 3.36 0.69 50.36 10.5 
English (22) 2.73 0.73 41.00 10.87 
0.031 
     
Publication Date     
 
2006-2009 (8) 2.91 0.82 43.63 12.26 
2010 or 2011 (16) 3.10 0.84 46.44 12.55 
Not available (9) 2.70 0.58 40.44 8.68 
0.476 
*Mann-Whitney U test for comparison of difference of mean DISCERN score of two groups; Kruskal-Wallis test for 
comparison of difference of mean DISCERN score of more than two groups; #as only one information provider displayed 4 
different quality labels and therefore the mean could not be calculated, this information material was excluded from the 
comparison. 
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5 Discussion 
The major findings of this study confirm that there is a wide variety of in-
formation available and easily accessible on the internet [37], but that only 
the minority of this information effectively meets the criteria for high-
quality patient information materials. 
In general, the quality of the included information materials is fair with a 
mean DISCERN rating of 44.12 (range 24 to 65). If one takes a closer look at 
each single DISCERN question, it becomes clear that the majority of the in-
cluded materials does neither explicitly nor implicitly state the option of re-
fusing treatment or refers to the decision of no treatment at all (mean DIS-
CERN score: 1.64). On the other hand, the fact that there is more than one 
treatment option available to treat CML (mean DISCERN score: 4.36) is 
addressed more often and more explicitly. Given the statement that there are 
more than one potential treatment options, one would assume that the bene-
fits and risks of each treatment option would be addressed to an equal ex-
tent. Although results regarding these two questions (DISCERN questions 
10 and 11) do not confirm this assumption, as their mean DISCERN score is 
around 3 (=partly). When assessing the information materials, it was noted 
that various treatment options were listed, but that a range of the materials 
does not describe benefits and harms of all options mentioned in the same 
detail but rather focuses on one specific treatment option. Thus, the infor-
mation included cannot be regarded as balanced in terms of content pro-
vided overall. Question 6 on the other hand aims to determine whether the 
information material is balanced and unbiased, which is rated above average 
(mean DISCERN score: 3.46), although this question refers to the structural 
quality of the information material, not the content presented. In 2002, Ey-
senbach et al. published a systematic review on the quality of health infor-
mation on the internet and found that most of the studies published until 
then criticised the difficulty of finding high-quality websites and lack of 
completeness and accuracy of the content presented on the websites [61]. 
Our findings support these conclusions. 
Evidence suggests that the origin of the information (information provider) 
is generally not associated with the quality of the information material pro-
vided. For instance, one would expect that information provided by univer-
sity institutions is of higher quality than information produced by organisa-
tions having a potential conflict of interest [62]. Due to the small number of 
included information materials, an analysis of the quality rating by informa-
tion provider was not feasible. Therefore, we grouped the information pro-
viders into three different categories – non-profit organisations, commercial 
organisations or others – showing significantly higher DISCERN ratings of 
information provided by non-profit organisations compared to that provided 
by commercial organisations (difference in mean DISCERN score: 0.89; 
p=0.012). Although there is a difference in quality rating regarding the type 
of information provider in our analysis, this might not be generalizable due 
to the small number of included information materials and further due to 
the different size of the groups compared. On the other hand, a study inves-
tigating written information provided and distributed by office-based gen-
eral practitioners in Berlin, Germany, found that the majority (>90%) of 
materials was produced by the pharmaceutical industry and that, informa-
tion provided may be accurate but it may, at the same time, be influencing 
due to incomplete and unbalanced information [2]. Another astonishing 
wide variety of 
information materials of 
different quality 
available 
overall, materials were 
of fair quality 
 
option of refusing 
treatment is generally 
not addressed 
 
despite making clear 
that more than one 
treatment option is 
available the benefits 
and risks for each option 
are not described in a 
balanced manner 
origin of the 
information generally 
not associated with the 
quality of the 
information material 
 
difference in quality 
rating between 
commercial and non-
profit organisations 
majority of information 
materials provided by 
commercial providers 
though information is 
accurate, it might be 
misleading at the same 
time 
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finding was that the quality of information materials offered by providers 
with quality certified websites did not differ from those that did not display 
a logo of quality certification on their website (p=0.385) or that the amount 
of quality labels displayed did not play a statistically significant role 
(p=0.055).  
To find materials or websites that provide comprehensive information about 
both, the disease itself and a complete description (mechanism of action, 
benefits and risks) of available treatment options, is challenging for a lay 
audience. Further, finding information sources that give information on the 
disease and its treatment options does not necessarily mean that this infor-
mation is accurate, relevant and comprehensive. For example, when we 
looked at the 516 links gathered during the first screening of the websearch, 
it turned out that only 15 (~3%) met our inclusion criteria. This would not 
have been surprising had the inclusion criteria been too narrow, but we al-
ready included information materials referring to at least one treatment op-
tion and not all currently available treatment options as depicted in the 
NCCN and ELN guidelines. This finding shows that not only the existence 
or availability but also the access to high-quality patient information is an 
essential part in SDM and health literacy. To address this need, several ini-
tiatives developed manuals for patients and health consumers intended to 
guide them through the jungle of health information available in the inter-
net. The recommendations in these manuals range from suggestions on how 
and where to search and choosing the right search terms to the statement of 
particularly trustworthy websites and an overview of trustworthy quality cer-
tifications (e.g. HON, AFGIS, etc.) [48]. On the other hand, there are initia-
tives supporting the implementation of independent high-quality, up-to-
date patient information and services (e.g.  
www.gesundheitsinformationen.de, MediSuch, www.patienten-
information.de) and medical and health care societies also develop and pro-
vide freely accessible treatment guidelines for patients (e.g.  
www.nccn.org/patients or www.uptodate.com/patients). 
To get an idea whether a website is trustworthy or not, one rather easy ap-
proach for patients and health consumers is to rely on the presence or ab-
sence of a quality seal on the website of an information provider. As good as 
this seems to be and the original intention was, one has to be careful when 
relying on the quality of the presented information only because the pro-
vider is approved by a quality label due to several reasons. First, the major-
ity of the criteria relevant to get a quality label refers to transparency and 
funding of the information provider, but does not refer to the accuracy and 
quality in terms of being comprehensive and balanced of the content at all. 
Those third party organisations providing such quality labels explicitly state 
that they do not rate the accuracy and balanced presentation of the content 
provided but that due to the commitment to transparency criteria by the in-
formation provider it is assumed that this also leads do more transparent, 
objective and qualitative information [63]. For the assessment of the content 
of the quality they refer to other rating instruments including DISCERN 
[63], which, itself does explicitly not assess the scientific quality and accu-
racy of  written consumer health information [58]. 
finding accurate, 
comprehensive and 
relevant information 
can be challenging for a 
lay audience 
 
 
not only the existence 
or availability but also 
the access to high-
quality information is 
essential in SDM 
 
guidelines to lead the 
lay audience through 
the jungle of health 
information were 
developed 
 
one approach is to 
depend on quality labels 
quality certifications 
aim to set apart 
trustworthy from non-
trustworthy websites 
criteria of quality labels 
mainly refer to 
transparency criteria 
and do not assess the 
accuracy and content 
quality of the 
information provided 
for the assessment of 
the quality of content 
other instruments are 
suggested (e.g. 
DISCERN) 
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Second, not all quality labels are awarded by independent third-party or-
ganisations. The Swiss Health Quality Association (SHQA), for example, is a 
registered association of pharmaceutical companies that aims to promote 
quality of communication and information in the health care setting. Al-
though the aim of SHQA is noteworthy, there is still a non-neglectable po-
tential for conflict of interest. 
Third, a study investigating the ability of a quality seal like HON to be an 
indicator of general and content quality of a health-related website was pub-
lished recently. Results of that study show that the HON label is not able to 
discern the reliability and accuracy of the content provided by an approved 
provider [62], which supports the criticism on rating instruments for medi-
cal websites by Eysenbach and Diepgen in 1998 [37]. They claim that these 
instruments are of questionable validity and reliability. Our findings recon-
firm this criticism and lead at the same time to the question whether DIS-
CERN is the most appropriate instrument to assess the quality of written 
consumer health information on different treatment options which remains 
open after this assessment. This might be due to the fact that internet in-
formation is changing too rapidly and dynamically to assure a good quality 
of the content of information and that these ratings are generally conducted 
by third parties, e.g. expert scientists who might not be aware of the patients’ 
needs and preferences [37]. 
Based on these findings it is recommended to prefer and rely on health in-
formation materials provided by non-commercial organisations rather than 
commercial organisations. Further, one should be aware of the fact that 
quality labels like HON, AFGIS or SHQA certify only transparency criteria 
of a website and not the content. Thus, in order to discriminate between low 
and high quality of written consumer health information health consumers 
as well as health professionals should use validated rating instruments like 
DISCERN when searching for or recommending written health information. 
before relying on a 
quality label inform 
yourself about the 
criteria underlying the 
certification 
quality certifications / 
labels are not able to 
discern the reliability 
and accuracy of the 
content 
 
question remains 
whether the quality of 
patient information can 
be assessed reliably with 
existing instruments 
within this rapidly and 
dynamically changing 
environment 
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6 Conclusion 
Information provided in the internet is widely unbalanced and incomplete 
and bears a substantial potential for conflict of interest. Major concerns are 
that information is often retrieved without the correct context (e.g. patients 
read information originally intended for physicians and/or do not read the 
preceding introduction to the information or even guideline and misinter-
pret the provided information) and that incorrect information can do more 
harm than good to the patient. As health information in the internet cannot 
be regulated as a whole, emphasis has to be put on helping patients to cope 
with the variety of information available and guide them through the jungle 
of information in order to enable them to access independent, accurate and 
reliable health information [37, 48]. Particular areas for improvement of the 
included patient information materials is, on the one hand, the comprehen-
sive provision of information about when, how and by whom the information 
was produced and which literature was used. On the other hand, the descrip-
tion of benefits and harms of each stated treatment option should be pre-
sented in a balanced way in order to enable patients to be well-informed and 
to participate actively in their treatment management process. 
 
information in the 
internet is widely 
unbalanced and 
incomplete 
 
incorrect information 
might do more harm 
than good to the 
patients 
 
particular areas of 
improvement are 
transparency and 
balanced presentation 
of the information 
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7 Limitations 
Our study has several limitations. First of all, we only included consumer 
health information in English and German and thus, results cannot be gen-
eralized within the European context. Second, in the course of our web-
search and handsearch, we might have missed relevant written patient in-
formation developed and distributed to the patients directly by physicians or 
other health care professionals. 
Further, the amount of finally included materials is too small to draw firm 
conclusions and the study looks at patient information about CML and its 
treatment options only, which is why conclusions cannot be drawn for pa-
tient information materials on leukaemia or in the general health care set-
ting at all.  
Another limitation might be that we conducted our websearch in widely 
used search engines, which are assumed to be more commonly used by the 
general population, rather than in medical search engines that might have 
focused more specifically on health-related issues. Internet users would 
probably combine search terms or would search by using other terms (e.g. 
rather disease-related terms than treatment-related terms) and would thus 
get different results. Further, we did not include a patient in the design of 
the search strategy or in conducting the search, selection of the relevant ma-
terials and quality appraisal of the included materials. We, therefore, are not 
able to judge how patients behave when selecting information from the web. 
However, as an additional handsearch including direct inquiries of relevant 
organisations was conducted, we assume to have gathered most of the writ-
ten health information on CML and its treatment options available that is 
freely accessible for health consumers through the internet. 
We used DISCERN for the quality appraisal of the included materials as it 
currently is the only standardized and validated instrument to assess the 
quality of written consumer health information on different treatment op-
tions. One substantial deficit of DISCERN is that it does not take the accu-
racy of the presented content into account. 
 
limitations: 
- language 
- identification of 
materials not available 
through the internet 
- search in widely used 
search engines rather 
than in medical search 
engines 
- search terms used 
might differ from those 
patients would chose 
- no patient was 
included in trial design, 
selection of materials 
and quality assessment 
- DISCERN does not take 
the accuracy of the 
information into 
account 
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8 Outlook 
It is evident that unbiased, reliable, comprehensive and accurate informa-
tion is becoming more and more important in times of SDM and that the 
quantity and importance of information provided via the internet is steadily 
increasing. Thus, one focus on future patient information has to deal with 
educating the patient on where to find reliable and unbiased information 
and to focus on improving health literacy in order to enable patients to un-
derstand the information provided and the medical and statistical terms 
used that are, to a certain extent, necessary and inevitable. 
Further, available criteria determining the quality of written consumer 
health information have to be incorporated in the development of patient in-
formation, knowing that not all criteria apply to each topic. Thereto analo-
gous the postulation on the advancement of an instrument to comprehen-
sively and reliably assess the quality of consumer health information has to 
be raised. Which admittedly is, due to the complexity of the construct “qual-
ity of written consumer health information”, a challenging task. 
 
need for unbiased, 
reliable, comprehensive 
and accurate 
information is 
increasing 
consider quality criteria 
of information materials 
already in the 
development 
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10 Appendix 
Table 10-1: List of institutions contacted directly for written patient information on CML 
Name Country Website Inclusion (yes/no) 
ACCESS Cancerlink The Nether-lands 
http://www.access-
nl.org/our_services/cancer_support.htm 
No - provide no 
patient info on 
CML 
AEAL- Asociacio´n Espan˜ola de Afecta-
dos por Linfomas, Mielomas y Leuce-
mias 
Spain http://www.aeal.es/ No - language 
American Cancer Society USA www.cancer.org Yes 
Arbeitsgemeinschaft fu¨r Internistische 
Onkologie (AIO) Germany http://www.aio-portal.de 
No - provide no 
patient info on 
CML 
Arcus-Onko Centrum Czech Republic http://arcus-oc.org/ No - language 
Asociacion Espanola Contra el Cancer 
(AECC) Spain 
https://www.aecc.es/Paginas/PaginaPrinc
ipal.aspx No - language 
Asociatia Romana impotriva Leucemiei 
(A.R.i.L.) Romania http://www.aril.ro/ No - language 
Associac¸a˜o Portuguesa contra a Leuce-
mia  Portugal http://www.apcl.pt/ No - language 
Associac¸a˜o Portuguesa de Leucemias e 
Linfomas Portugal http://www.apll.org/teste/ No - language 
Association for help in treatment of pa-
tients with CML Macedonia 
Not accessible (retrieved via 
www.cmladvocates.net)  No - language 
Association Laurette Fugain France http://www.laurettefugain.org/ No - language 
Association of cancer patients from 
Romania (ABC) Romania http://www.srccjro.org/index_en.htm No - language 
Association of European Cancer 
Leagues (ECL) Europe http://www.europeancancerleagues.eu/ 
No - provide no 
patient info on 
CML 
Association of People Suffering from 
CML Bulgaria http://www.hml-bg.com/ No - language 
Association of Support for Leukemia 
Patients (Leikemijas slimnieku atbalsta 
biedriba) 
Latvia www.leikemija.lv No - language 
Association P.A.V.E.L. Romania http://www.asociatiapavel.ro 
No - provide no 
patient info on 
CML 
Associazione Italiana Contro le Leuce-
mie (AIL) Italy http://www.ail.it/ No - language 
Associazione Italiana Malati di Cancro Italy http://www.aimac.it/ No - language 
Associazione Malati Oncologici (AMO) Italy http://www.associazionemalationcologici.org/ No - language 
Associazione per il sostegno oncologico Italy http://www.aseop.it No - language 
"Birlikde" Leukemia Patients Support 
Organisation Azerbaijan www.leykemiya.az No - language 
Blodcancerfo¨rbundet Sweden http://www.blodcancerforbundet.se/ No - language 
Blood Cell Foundation for children with 
cancer diseases Poland http://www.krwinka.org/ No - language 
Bradford Cancer Support UK http://www.bradfordcancersupport.org.uk/ 
No - provide no 
patient info on 
CML 
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Name Country Website Inclusion (yes/no) 
Bristol Mayer Squibb Austria / In-ternational  
http://www.b-
ms.at/index.php?set_language=de&cccpa
ge=bms_willkommen 
Yes 
Bulgarian Association for Patients De-
fense Bulgaria 
http://www.patient.bg/index_en.php?pa
ge_id=15 No - language 
Cancer Care UK http://www.cancercare.org.uk/ No - duplicate 
Cancer Equality UK http://www.cancerequality.org.uk/ 
No - provide no 
patient info on 
CML 
Cancer Information and Support Service UK http://www.cancerinformation.org.uk/ 
No - provide no 
patient info on 
CML 
Cancer Patients Society of Macedonia-
Thrace Greece http://afroditi.uom.gr/skmth/ No - language 
Cancer Research UK UK http://www.cancerresearchuk.org/ Yes 
Cancer.Net USA 
http://www.cancer.net/patient/Cancer+T
ypes/Leukemia+-+Chronic+Myeloid+-
+CML 
Yes 
Cancerfonden Sweden http://www.cancerfonden.se No - language 
Central European Leukemia Study 
Group (CELSG) Europe http://www.cml-info.com/ Yes 
Children with Cancer UK http://www.childrenwithcancer.org.uk/ 
No - provide no 
patient info on 
CML 
Children with CML UK http://www.childrenwithcml.org.uk/home.asp?parent_id=1 No - duplicate 
Children’s Cancer and Leukaemia Group 
(CCLG) UK http://www.cclg.org.uk/index.php 
No - provide no 
patient info on 
CML 
Chronic Myeloid Leukemia Canada http://www.cmleukemia.com/index.html 
No - provide no 
patient info on 
CML 
CML & GIST Beteg Egyesu¨let Hungary http://www.cmlgist.hu/ No - language 
CML Advocates Network Ireland http://cmladvocates.net/ No - duplicate 
CML Alliance by Novartis http://www.cmlalliance.net/novartis-commitment/faqs.jsp Yes 
CML Association of Serbia Serbia http://www.cml.rs/ No - language 
CML Support UK http://www.cmlsupport.org.uk/ No - FAQs and video 
CML-Info Austria http://www.cml-info.com/de.html Yes 
Croation Leukemia and Lymphoma So-
ciety (HULL: Hrvatska udruga leuke-
mija i limfomi) 
Croatia http://www.hull.hr/ No - language 
Deutsche Gesellschaft fu¨r Ha¨matologie 
und Onkologie e. V. (DGHO) Germany http://www.dgho.de/ 
No - provide no 
patient info on 
CML 
Deutsche Krebshilfe e.V. Germany http://www.krebshilfe.de/ Yes 
Diagnoza CML Czech Republic http://diagnoza-cml.cz/ No - language 
Die Leuka¨miehilfe Rhein-Main g.e.V Germany http://www.leukaemiehilfe-rhein-main.de/ 
No - provide no 
patient info on 
CML 
Eesti Leukeemia ja Lu¨mfoomihaigete 
Liit (Estonian Leukaemia and Lym-
phoma Patients Society) 
Estonia http://www.leukeemia.ee/ No - language 
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Name Country Website Inclusion (yes/no) 
Estonian Cancer Society Estonia http://www.cancer.ee/?op=body&id=15&cid= 
No - provide no 
patient info on 
CML 
EUROCARE Europe http://www.eurocare.it/ 
No - provide no 
patient info on 
CML 
European Action Against Rare Cancers Europe http://www.rarecancers.eu/ 
No - provide no 
patient info on 
CML 
European Cancer Observatory Europe http://eu-cancer.iarc.fr/ 
No - provide no 
patient info on 
CML 
European Cancer Organisation (ECCO) Europe http://www.ecco-org.eu/ 
No - provide no 
patient info on 
CML 
European Cancer Patient Coalition Europe http://www.ecpc-online.org/ 
No - provide no 
patient info on 
CML 
European Leukemia Information Center 
(ELIC) Europe 
http://www.kompetenznetz-
leukaemie.de Yes 
European Organisation for Research 
and Treatment of Cancer (EORTC) Europe http://www.eortc.org/ 
No - provide no 
patient info on 
CML 
European Society for Medical Oncology 
(ESMO) Europe http://www.esmo.org/ 
No - provide no 
patient info on 
CML 
"Fighting and Preventing Lymphoma 
and Leukemia" Leukemia Association Romania www.leukemia.ro  No - language 
Flemish Cancer Leagua Belgium http://www.tegenkanker.be/ No - language 
Fondation Cancer Luxembourg http://www.cancer.lu/ 
No - provide no 
patient info on 
CML 
Fondation Contre le Cancer Belgium http://www.cancer.be/ No - language 
France Federation Leucemie Espoir France http://www.leucemie-espoir.org/ No - language 
German Cancer Society (DKG) Germany http://www.krebsgesellschaft.de/ Yes 
German Leukemia and Lymhoma Aid 
(DLH, Deutsche Leuka¨mie- und Lym-
phom-Hilfe e.V.) 
Germany http://www.leukaemie-hilfe.de/ Yes 
Gruppo Ail Pazienti Leucemia Mieloide 
Cronica Italy http://www.lmconline.it No - language 
Hungarian League Against Cancer Hungary http://www.rakliga.hu/ No - language 
International Agency for Research in 
Cancer International http://www.iarc.fr/ 
No - provide no 
patient info on 
CML 
International Chronic Myeloid Leuke-
mia Foundation (iCMLf) Europe http://www.cml-foundation.org/ 
No - provide no 
patient info on 
CML 
Irish Cancer Society Ireland http://www.cancer.ie/ Yes 
Kankerbestrijding/KWF The Nether-lands 
http://www.kwfkankerbestrijding.nl/Pag
es/Home.aspx No - language 
Kosovo Association for Supporting 
Chronic Leukemia Patients Kosovo 
Not accessible (retrieved via 
www.cmladvocates.net) No - language 
Kraeftens Bekaempelse (Danish Cancer 
Society) Denmark 
http://www.cancer.dk/om+os/The+Danis
h+Cancer+Society.htm No - language 
Krebsliga Schweiz Switzerland http://www.krebsliga.ch Yes 
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Krebspatienten-Info (Initiative der 
OeGHO) Austria 
http://www.krebspatienten.info ODER 
http://bluterkrankungen.info No - duplicate 
La Ligue Nationale Contre le Cancer France http://www.ligue-cancer.net/ No - language 
Latvian Support Society for Oncology 
Patients "Dzivibas koks" Latvia http://www.dzivibaskoks.lv/ No - language 
League Against Cancer Prague Czech Republic http://www.lpr.cz No - language 
League Against Cancer Slovakia Slovakia http://www.lpr.sk/ No - language 
Leucemia CARE UK http://www.leukaemiacare.org.uk/1/home.html 
No - provide no 
patient info on 
CML 
Leucemie espoir 06 France http://www.leucemie-espoir.org/spip.php?rubrique113  No - language 
Leukaemia & Lymphoma Research UK http://www.beatbloodcancers.org/ Yes 
Leuka¨mie Kompetenznetz Germany http://www.kompetenznetz-leukaemie.de/content/home/ Yes 
Leuka¨mie-Online / LeukaNET Germany http://www.leukaemie-online.de/ 
NO - provide no 
patient info on 
CML; exchange 
portal 
Leukemia & Lymphoma Society - fight-
ing blood cancers Canada http://www.lls.org Yes 
LMC France France http://lmcfrance.jimdo.com/  No - language 
LYLE, Association for lymphatic cancer 
and leukemia Denmark http://www.cancer.dk/lyle/ No - language 
Macmillian Cancer Support UK http://www.macmillan.org.uk/Home.aspx 
Yes - duplicate 
(internet search)
Mayo Clinic USA http://www.mayoclinic.com/health/chronic-myelogenous-leukemia/DS00564 Yes 
National Association of Patients with 
Oncological Diseases (APOZ) Bulgaria http://oncobg.info/ No - language 
National Cancer Research Network UK http://www.ncrn.org.uk/ 
No - provide no 
patient info on 
CML 
National CML Society USA www.nationalcmlsociety.org Yes 
Norwegian Cancer Society Norway http://www.kreftforeningen.no/english No - language 
Novartis Austria / In-ternational http://www.glivec.com/index.jsp No - duplicate 
Novartis Austria / In-ternational  http://www.novartis.at/index.shtml No - duplicate 
Oncosuisse Switzerland http://www.oncosuisse.ch/ 
No - provide no 
patient info on 
CML 
Organisation of European Cancer Insti-
tutes Europe http://www.oeci-eeig.org/ 
No - provide no 
patient info on 
CML 
OSANNA Ukraine http://osanna.com.ua/ No - language 
O¨sterreichische Krebshilfe Austria http://www.krebshilfe.net/home.shtm 
No - provide no 
patient info on 
CML 
PASYKAF - The Cyprus Association of 
Cancer Patients and Friends Cyprus http://www.pasykaf.com/ No - language 
Patient Association of Rare Oncological 
Diseases Lithuania http://www.nonasoft.lt/Rolld/ No - language 
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Patientenforum Switzerland http://www.patientenforum.ch/ 
No - provide no 
patient info on 
CML 
Patients Association UK http://www.patients-association.com/ 
No - provide no 
patient info on 
CML 
Polskie Stowarzyszenie Pomocy 
Chorym na Szpiczaka Poland http://www.szpiczak.org.pl No - language 
Rarer Cancers Foundation UK http://www.rarercancers.org.uk/ 
No - provide no 
patient info on 
CML 
Romanian Cancer League Romania www.romaniancancerleague.org No - language 
SCL Stichting Contactgroep Leukemie The Nether-lands http://www.leukemie.nfk.nl/ No - language 
Slovenian lymphoma and leukemia pa-
tient association, L&L Slovenia http://www.limfom-levkemija.org/ No - language 
Society of Oncolhaematological Pa-
tients "Kraujas" Lithuania http://www.kraujas.lt/ No - language 
Sodeystvie (Assistance) Russia http://www.sodeystvie-cml.ru/  No - language 
Stiftung zur Fo¨rderung der Knochen-
marktransplantation (SFK) Switzerland www.knochenmark.ch  Yes 
Swiss Group for Clinical Cancer Re-
search (SAKK) Switzerland http://sakk.ch/en/ 
No - provide no 
patient info on 
CML 
The European Association for Cancer 
Research (EACR) Europe http://www.eacr.org/ 
No - provide no 
patient info on 
CML 
The European LeukemiaNet Europe http://www.leukemia-net.org/content/home/ 
No - provide no 
patient info on 
CML 
The Finnish CML Patient Network Finland   No - page not accessible 
The Nationwide Association for CML 
Patient Aid (Stowarzyszenie PBS) Poland http://www.spbs.com.pl/  No - language 
Vivre avec la LMC France http://vivreaveclalmc.org/ No - language 
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Figure 10-1: Distribution of the overall DISCERN rating across included information materials 
